Mounjaro vs. Saxenda
See how Mounjaro and Saxenda compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Mounjaro is FDA-approved for type 2 diabetes and used off-label for weight loss, while Saxenda is FDA-approved specifically for chronic weight management in adults and teens.
Mounjaro is injected once a week; Saxenda requires a daily injection with a four-week titration before reaching its single maintenance dose.
Both carry a boxed warning for thyroid C-cell tumors, but Saxenda's label adds warnings about increased heart rate and suicidal thoughts.
Mounjaro vs. Saxenda Drug Summary
Mounjaro
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist FDA-approved to control blood sugar in adults and children 10 and older with type 2 diabetes. It is injected once a week, with the dose slowly raised from 2.5 mg up to as much as 15 mg over about five months. Many prescribers also use it off-label for weight loss.
Saxenda
Saxenda (liraglutide) is a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in teens 12 to 17 with obesity. It is injected once a day, with the dose raised weekly from 0.6 mg to a 3 mg maintenance dose over one month. It is not approved to treat diabetes.
Mounjaro vs. Saxenda Side Effects
Mounjaro
Saxenda
Mounjaro vs. Saxenda Dosage
Mounjaro
Saxenda
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 3 mg once daily | Week 5 onward |
| Dose changes | 4 increases | Every week |
Mounjaro
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
Saxenda
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 3 mg once daily | Week 5 onward |
| Dose changes | 4 increases | Every week |
Mounjaro vs. Saxenda Indications
Mounjaro
Mounjaro's only FDA-approved use is blood sugar management in type 2 diabetes. Using it for weight loss in people without diabetes is off-label, though it's a common practice built on strong clinical trial results.
Blood sugar control in adults with type 2 diabetes
Blood sugar control in pediatric patients 10 years and older with type 2 diabetes
Off-label use for weight loss in people without diabetes
Not approved for type 1 diabetes
Saxenda
Saxenda's FDA approval is specifically for chronic weight management, not diabetes. It works for adults with obesity, or with overweight plus a weight-related condition like high blood pressure, and for teens ages 12 to 17 with obesity.
Chronic weight management in adults with obesity or overweight plus a weight-related condition
Chronic weight management in adolescents 12-17 with obesity
Not approved for type 1 or type 2 diabetes (that's Victoza)
Not approved for use during pregnancy
Mounjaro vs. Saxenda Pros and Cons
Mounjaro
Mounjaro's dual-hormone mechanism has shown strong results for both blood sugar and weight, and once-weekly dosing fits easily into most routines. Because it isn't FDA-approved for weight loss on its own, insurance coverage for that use can be inconvenient to secure.
Pros
Once-weekly injection instead of a daily shot
Dual GIP/GLP-1 mechanism, the first of its kind
FDA-approved specifically for blood sugar control in type 2 diabetes
Higher maximum dose (15 mg) gives more room to escalate if needed
Cons
Weight loss use is off-label, which can complicate insurance approval
Longer titration period, about five months to reach the top dose
Contraindicated in patients with severe gastroparesis
Newer to market, so less long-term real-world safety data
Saxenda
Saxenda has been on the market since 2014 and is FDA-approved specifically for weight management, including in teens, so coverage doesn't hinge on off-label use. It requires a daily injection, and its label carries extra warnings around heart rate and mood that Mounjaro's does not include.
Pros
FDA-approved specifically for weight loss, not an off-label use
Approved for adolescents 12-17 with obesity
Over a decade of real-world use and safety data since 2014
Reaches its maintenance dose in just five weeks
Cons
Requires a daily injection instead of a weekly one
Higher rates of nausea and diarrhea reported in trials
Added label warnings for increased heart rate and suicidal thoughts
Cannot be used for blood sugar control in diabetes (Victoza is the diabetes version)
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.